Harrington Seeks Innovators to Bridge Lab-to-Bedside 'Valley of Death'

CLEVELAND, OH – April 21, 2026 – The Harrington Discovery Institute at University Hospitals has officially opened the call for applications for its 2027 Harrington Scholar-Innovator Award, a prestigious program designed to shepherd promising medical discoveries from the lab to the patient's bedside. The initiative targets a critical gap in medicine known as the “valley of death,” where groundbreaking research often stalls due to a lack of funding and commercialization expertise.

By offering a unique combination of financial support and hands-on guidance from pharmaceutical industry veterans, the award provides a vital lifeline for physician-scientists across the United States and Canada. Successful applicants receive a guaranteed $100,000 grant, the chance to compete for up to $300,000 in acceleration funds, and the opportunity to qualify for investment capital that typically reaches up to $2 million. The application deadline for this transformative opportunity is June 22, 2026.

A Lifeline Across the Translational Abyss

For many physician-scientists, the journey from a breakthrough discovery to a viable therapeutic is fraught with peril. The challenges are numerous: securing sustained funding, navigating the complex regulatory landscape, and acquiring the specialized business and drug development knowledge that is rarely taught in medical school or academic research settings. This chasm between academic innovation and commercial viability is the “valley of death” where countless potential cures languish.

The Harrington Scholar-Innovator Award was created to directly address these hurdles. Unlike traditional research grants that primarily provide capital and then step back, the Harrington model offers a comprehensive support system. The institute’s Therapeutics Development Center (TDC) is central to this approach, providing each scholar with a dedicated team of advisors—seasoned professionals with track records of bringing drugs to market. These experts offer guidance on everything from medicinal chemistry and preclinical planning to intellectual property strategy and commercial development.

A key feature that sets the program apart is its policy on intellectual property. Award recipients and their host institutions retain all IP rights to their discoveries. This is a significant incentive for innovators, allowing them to maintain control over their work while benefiting from the institute's vast resources and expertise. This approach fosters a truly collaborative partnership rather than a transactional one, empowering scientists to lead their projects forward.

A Proven Model for Medical Breakthroughs

Since its inception in 2012 with a $50 million founding gift from the Harrington family, the institute has built an impressive track record of success. The model is not just a theoretical solution but a proven engine for medical innovation. To date, Harrington Discovery Institute has supported 214 drug-discovery projects, which have led to the launch of 43 companies.

More importantly, the support has translated into tangible clinical progress. The institute’s portfolio has produced 21 clinical candidates and resulted in 15 licensing deals with pharmaceutical companies, moving novel treatments for conditions like cancer, heart disease, and rare genetic disorders closer to the patients who need them. One drug for heart attacks, advanced with the institute's support, has already entered clinical trials.

The program’s success stems from its blended non-profit/for-profit structure. Philanthropic dollars are used to de-risk early-stage projects, making them more attractive for later-stage investment. Scholars gain access to Harrington's mission-aligned commercial partners, including the for-profit company BioMotiv and the Advent-Harrington Impact Fund, which provide pathways for significant follow-on funding and commercialization.

Fueling a Global Innovation Ecosystem

The impact of the Harrington Discovery Institute extends beyond individual projects, contributing to a robust regional and global biotech ecosystem. As an integral part of University Hospitals in Cleveland, the institute is a key component of a health system that generated over $14 billion in economic output for Ohio in 2023. By nurturing scientific talent and spinning out new companies, it helps solidify the region's standing as a hub for medical innovation.

However, the institute's vision is global. Its network now includes 74 institutions across the United States, Canada, and the United Kingdom. A flagship partnership with the University of Oxford created the Oxford-Harrington Rare Disease Centre, which aims to accelerate the development of treatments for the more than 300 million people worldwide affected by rare diseases. This collaboration recently launched a Therapeutics Accelerator with an initial commitment of up to $250 million and an ambitious goal to bring 40 rare disease medicines into clinical trials by 2034.

As Harrington Discovery Institute invites the next cohort of innovators to apply for the 2027 award, the call represents more than just a funding opportunity. It is an invitation for physician-scientists to join a proven ecosystem dedicated to converting the promise of their research into the reality of new cures. The selections, to be made by the institute's esteemed Scientific Advisory Board, will be announced in March 2027, launching another wave of potential breakthroughs in the ongoing quest to address unmet medical needs.